ACE inhibitors for sarcopenia--as good as exercise training?

10. Nair N, Oka RK, Waring LD et al. Vascular compliance versus flow-mediated dilatation: correlation with cardiovascular risk factors. Vasc Med 2005; 10: 275–83. 11. Wilkinson IB, MacCallum H, Cockcroft JR et al. Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity in vivo. Br J Clin Pharmacol 2002; 53: 189–92. 12. Stewart AD, Millasseau SC, Kearney MT et al. Effects of inhibition of basal nitric oxide synthesis on carotid-femoral pulse wave velocity and augmentation index in humans. Hypertension 2003; 42: 915–8. 13. Bulpitt CJ, Rajkumar C, Cameron JD. Vascular compliance as a measure of biological age. J Am Geriatr Soc 1999; 47: 657–63. 14. Rossouw JE. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33. 15. Haddad RM, Kennedy CC, Caples SM et al. Testosterone and cardiovascular risk in men: a systematic review and metaanalysis of randomized placebo-controlled trials. Mayo Clin Proc 2007; 82: 29–39. 16. Lane HA, Grace F, Smith JC et al. Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids. Eur J Clin Invest 2006; 36: 483–8. 17. McCredie RJ, McCrohon JA, Turner L et al. Vascular reactivity is impaired in genetic females taking high-dose androgens. J Am Coll Cardiol 1998; 32: 1331–5. 18. Ong PJL, Patrizi G, Chong WCF et al. Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease. Am J Cardiol 2000; 85: 269–72. 19. Dockery F, Bulpitt CJ, Agarwal S et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci 2003; 104: 195–201. 20. Swartz CM, Young MA. Low serum testosterone and myocardial infarction in geriatric male inpatients. J Am Geriatr Soc 1987; 35: 39–44. 21. Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronaemia with coronary artery disease in men. Arterioscler Thromb 1994; 14: 701–6. 22. Webb CM, Elkington AG, Kraidly MM et al. Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease. Am J Cardiol 2008; 101: 618–24, Epub 2007 Dec 21. 23. English KM, Steeds RP, Jones TH et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebocontrolled study. Circulation 2000; 102: 1906–11. 24. Ishihara F, Hiramatsu K, Shigematsu S et al. Role of adrenal androgens in the development of arteriosclerosis as judged by pulse wave velocity and calcification of the aorta. Cardiology 1992; 80: 332–8. 25. Hougaku H, Fleg JL, Najjar SS et al. Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements. Am J Physiol Endocrinol Metab 2006; 290: E234–42. 26. Perheentupa A, Huhtaniemi I. Does the andropause exist? Nat Clin Pract Endocrinol Metab 2007; 3: 670–1. 27. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 2008; 299: 39–52. 28. Isidori AM, Giannetta E, Greco EA et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol 2005; 63: 280–93.